Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

US: District Court S D New York: ‘Isolated DNA’ patents fail to claim patentable subject matter: Association for Molecular Pathology and ACLU v. USPTO and Myriad Genetics (Docket Report) (Peter Zura’s 271 Patent Blog) (Inventive Step) (Patently-O) (Holman’s Biotech IP Blog) (Patent Docs) (Ladas & Parry) (Tech Transfer Blog) (ipwars.com) (Ars Technica) (BlawgIT) (IP Watch) (The Prior Art)

Lee, Bio 2010 and global biotech innovation investment and jobs (IP Think Tank)

Pointed exchange of views at WHO briefing on counterfeit drugs (IP Watch)

WHO undertakes independent review of its pandemic flu efforts (IP Watch)

Monsanto’s patent strategy: Less today may be more tomorrow (IP finance)

What is implied by a patent under international law? – TRIPS and price controls on patented pharmaceutical products (patentidbits)

Assessing pharma patent strength (JIPLP)

Canada: Health Canada releases final guidances on biosimilars (Pharmacapsules)

US: District Court S D New York: ‘Isolated DNA’ patents fail to claim patentable subject matter: Association for Molecular Pathology and ACLU v. USPTO and Myriad Genetics (Docket Report) (Peter Zura’s 271 Patent Blog) (Inventive Step) (Patently-O) (Holman’s Biotech IP Blog) (Patent Docs) (Ladas & Parry) (Tech Transfer Blog) (ipwars.com) (Ars Technica) (BlawgIT) (IP Watch) (The Prior Art)

US: Study suggests USPTO erred in broad claims of Myriad BRCA1 patent (Tech Transfer Blog) (Patent Docs)

US: CAFC confirms written description requirement in Ariad v Lilly (IP Law Blog) (IP Osgoode) (IP Spotlight) (Ars Technica)

US: Justifying the decision in Ariad v Lilly (Patently-O)

US: Ariad v Lilly: Choosing to not disrupt the settled expectations of the patent community (Patently-O)

US: CAFC affirms BPAI rejection of claims (relating to method for converting drug dosages to prevent overdose) on grounds of obviousness: In re Arora (Patent Docs)

US: CAFC wades into patent ownership dispute Applera Corp. v Illumina, Inc (not precedential) (Patent Docs)

US: Gen-Probe files patent infringement suit in S D California against Becton, Dickinson & Co based on their BD MAX System nucleic acid testing system (Patent Docs)

US: District Court E D Texas: False marking complaint filed based on DDAVP products: Promote Innovation LLC v Sanofi-Aventis US LLC (Patent Docs)

US: False patent marking bill introduced in the House (Patent Docs)

US: PUBPAT expresses ‘deep concern’ over Senate false marking provision (Patent Docs)

Allegra D 12 Hour (Fexofenadine) – US: Sanofi-Aventis files patent infringement suit against Wockhardt following Para IV challenge (Patent Docs)

Angiomax (Bivalirudin) – US: Here we go again! MDCO launches another lawsuit against the PTO over Angiomax PTE (FDA Law Blog)

Arzerra (Ofatumumab) – US: Biogen files patent infringement suit in S D California against Glaxosmithkline based on manufacture and sale of Arzerra (Patent Docs)

Arzerra (Ofatumumab) – US: Genetech files counterclaims in declaratory judgment suit brought by GlaxoSmithKline (Patent Docs)

Astelin (Azelastine) – US: District Court New Jersey: Patent infringement complaint following Para IV challenge: Meda Pharmaceuticals Inc v Zydus Pharmaceuticals USA, Inc (Patent Docs)

Baraclude (Entecavir) – India: Delhi High Court refuses Bristol-Myers Squibb’s application for ex-parte injunction order against Ranbaxy (Spicy IP) (Generic Pharmaceuticals)

Carbatrol (Carbamazepine) – US: Settlement announced in Carbatrol suit between Shire and Nostrum Pharmaceuticals (Patent Docs)

Cipralex (Escitalopram) – Israel: Lundbeck loses again in battle for patent term extension: this time in the Supreme Court (IP Factor)

Cozaar (Losartan): FDA rules against patent expiration 180-day exclusivity forfeiture for generic Cozaar/Hyzaar, but in doing so FDA repudiates its own decision and asks to be sued (FDA Law Blog)

Doryx (Doxycycline) – US: District Court New Jersey: Patent infringement complaint following Para IV challenge: Warner Chilcott Co., LLC et al v Heritage Pharmaceuticals Inc (Patent Docs)

Gemzar (Gemcitabine) – US: Eli Lilly files patent infringement suit in S D Indiana against Hospira following Para IV challenge (Patent Docs)

Nexavar (Sorafenib) – India: Bayer sues Cipla for patent infringement on Sorafenib (Generic Pharmaceuticals)

Viagra (Sildenafil) – Brazil: Patent protection in Brazil: is this the end for Viagra? (IP tango)

Zyprexa (Olanzapine) – Netherlands: District Court of The Hague finds Olanzapine patent and SPC invalid: Ratiopharm v. Eli Lilly (EPLAW)